IMNM
Immunome Inc.
NASDAQ · Healthcare · Biotechnology · US
$16.77
+1.82%Year over year
Reported trailing growth
- Revenue
- -100.0%
- EBITDA
- -38.0%
- EBIT
- -20.4%
- EPS
- +17.5%
- Free cash flow
- -17.7%
- Operating cash flow
- -16.9%
Forward estimates
Based on analyst estimates
- Revenue
- —
- EBITDA
- -14.5%
- EPS
- -1.5%
Three-year CAGR
- Revenue
- -29.6%
- EBITDA
- -38.4%
- EBIT
- +30.0%
- Net income
- +27.5%
- EPS
- +51.4%
- Free cash flow
- -22.1%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Jun 1, 2026